Healthcare Providers' Vaccination Against COVID-19: Safety Concerns
International Pharmacy Acta,
Vol. 7 No. 1 (2024),
24 July 2024
,
Page e2: 1-7
https://doi.org/10.22037/ipa.v7i1.45396
Abstract
This study examined parameters that may affect the severity and type of side effects associated with COVID-19 vaccine administration at Imam Khomeini Hospital in Ardabil, Iran. Based on a reliable and valid questionnaire, data were collected from 149 hospital employees at random. 77.2% of the study participants were women, and 52% were between the ages of 30-39. Approximately 50% of the participants had a healthy body mass index. Of the participants, 76.5% had no underlying disease. The prevalence of complications after injection of the first dose (regardless of vaccine type) included fever (45%), chills (28.3%), injection site complications (34.9%), myalgia (46.3%), weakness and fatigue (43%), headache (24.2%), thrombocytopenia (1.3%), cough (4%), nausea (6.7%), diarrhea (6.7%), and other complications (5.4%). After receiving a second dose, the most frequently reported adverse reactions were fatigue and weakness. This pattern was repeated for third dose. Injection of the first dose of vaccine induced the most severe side effects. The results demonstrated a significant relationship between severity and duration of side effects and participants' age, sex, body mass index, diet quality, physical activity, and complementary medicines. Participants with underlying health conditions and those using corticosteroids had higher adverse effects incidences. A significant positive correlation (0.878%) was observed between fever severity and chills. SputnikV and AstraZeneca vaccines were associated with more side effects. In general, the rate and severity of side effects after vaccination are directly related to female gender, low body mass index, previous infection, and young age.
- COVID-19
- Vaccination
- Side effects
- Health Personnel
How to Cite
References
Alemayehu A, Demissie A, Yusuf M, Abdullahi Y, Abdulwehab R, Oljira L, et al. COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study. SAGE Open Medicine. 2022;10:20503121221108616.
Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. British Medical Journal Publishing Group; 2021.
Aliasgarzade S, Matin S, Javaheri N, Aliasgarzade J, Aghamohammadi V. Coagulation disorders in hospitalized COVID-19 patients and relationship with disease outcome: A cross-sectional study. Archives of Clinical Infectious Diseases. 2021;16(5).
Aliasgarzadeh S, Arabzadeh A, Fathibitaraf S, Negaresh M. Sudden development of the upper and lower limb ischemia as the first manifestation of COVID-19 infection. International Journal of Surgery Case Reports. 2022;96:107332.
Ramezani A, Sorouri R, Haji Maghsoudi S, Dahmardeh S, Doroud D, Sadat Larijani M, et al. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. Scientific Reports. 2023;13(1):8065.
Li L, Honda-Okubo Y, Baldwin J, Bowen R, Bielefeldt-Ohmann H, Petrovsky N. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55. 2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine. 2022;40(23):3182-92.
Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Scientific reports. 2021;11(1):21464.
Pagotto V, Ferloni A, Soriano MM, Díaz M, Braguinsky Golde N, González MI, et al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. MEDICINA (Buenos Aires). 2021;81(3).
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of clinical medicine. 2021;10(7):1428.
Enayatrad M, Mahdavi S, Aliyari R, Sahab-Negah S, Nili S, Fereidouni M, et al. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC infectious diseases. 2023;23(1):150.
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases. 2021;111:219-26.
Yan Z-P, Yang M, Lai C-L. COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals. 2021;14(5):406.
Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC medicine. 2021;19:1-16.
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583-9.
Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. International immunopharmacology. 2021;101:108351.
Kumar Singh A, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. Antibody Response after Second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study. medRxiv. 2021:2021.06. 02.21258242.
Al Bahrani S, Albarrak A, Alghamdi OA, Alghamdi MA, Hakami FH, Al Abaadi AK, et al. Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia. International Journal of Infectious Diseases. 2021;110:359-62.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.
Azzi L, Toia M, Stevanello N, Maggi F, Forlani G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID‐19 vaccine. Oral diseases. 2021.
Kale P, Gupta E, Bihari C, Patel N, Rooge S, Pandey A, et al. Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. medRxiv. 2021:2021.06. 28.21259546.
Jahan N, Rahman FI, Saha P, Ether SA, Roknuzzaman A, Sarker R, et al. Side effects following administration of the first dose of Oxford-AstraZeneca’s Covishield vaccine in Bangladesh: a cross-sectional study. Infectious Disease Reports. 2021;13(4):888-901.
Babaee E, Amirkafi A, Tehrani-Banihashemi A, SoleimanvandiAzar N, Eshrati B, Rampisheh Z, et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases. 2022;22(1):476.
- Abstract Viewed: 177 times
- IPA-2024 Vol7i1-e2 Downloaded: 194 times